Vaxxinity Valuation Multiples

Vaxxinity is valued at $13K. In the last fiscal year, Vaxxinity EBITDA was ($56M).

Vaxxinity Overview

About Vaxxinity

Vaxxinity Inc is a biotechnology company committed to democratizing healthcare across the globe. The company is pioneering a new class of synthetic, peptide-based active immunotherapy medicines aimed at disrupting the existing treatment paradigm for chronic disease, increasingly dominated by monoclonal antibodies, which suffer from prohibitive costs and cumbersome administration. The company’s proprietary technology platform has enabled the innovation of novel pipeline candidates designed to bring the efficiency of vaccines to the treatment of chronic diseases, including Alzheimer’s, Parkinson’s, migraine, and hypercholesterolemia.


Founded

2021

HQ

United States

Employees

65

Financials (Last FY)

Revenue: -
EBITDA: ($56M)

EV

$13K

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Vaxxinity Financials

Vaxxinity reported last fiscal year revenue of - and negative EBITDA of ($56M).

In the same fiscal year, Vaxxinity generated ($56M) in EBITDA losses and had net loss of ($57M).


Vaxxinity P&L

In the most recent fiscal year, Vaxxinity reported revenue of - and EBITDA of ($56M).

Vaxxinity is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.

See analyst estimates for Vaxxinity
Last FY2023202620272028
EBITDA($56M)($56M)
Net Profit($57M)($57M)
Net Debt$10M-

Financial data powered by Morningstar, Inc.

Vaxxinity Stock Performance

Vaxxinity has current market cap of $13K, and enterprise value of $13K.

EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$13K$13K-----

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Vaxxinity Valuation Multiples

Vaxxinity trades at (0.0x) EV/EBITDA.

See NTM and 2027E valuation multiples for Vaxxinity

Vaxxinity Financial Valuation Multiples

As of November 19, 2026, Vaxxinity has market cap of $13K and EV of $13K.

Vaxxinity has a P/E ratio of (0.0x).

Last FY2023202620272028
EV/EBITDA(0.0x)(0.0x)
EV/EBIT(0.0x)(0.0x)
P/E(0.0x)(0.0x)
EV/FCF(0.0x)(0.0x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Vaxxinity Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Vaxxinity Operational KPIs

Vaxxinity's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.9M for the same period.

Access forward-looking KPIs for Vaxxinity
Last FY202620272028
Revenue per Employee$0.0M
Opex per Employee$0.9M

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Vaxxinity Competitors

Vaxxinity competitors include Scorpius Holdings, Neovacs, Novaccess Global, M2Bio Sciences, Acutus Medical, Virpax Pharmaceuticals, Lipella Pharmaceuticals, Allurion, Lyra Therapeutics and Ocean Biomedical.

Most Vaxxinity public comparables operate across Biopharmaceuticals, Medical Devices and BioTech.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Scorpius Holdings$6M($26M)1.9x-(0.5x)-
Neovacs$356K($6M)2.2x-(0.1x)-
Novaccess Global-($2M)--(0.0x)-
M2Bio Sciences$80M$3M0.0x-0.0x-
Acutus Medical$20M$759K0.0x-0.0x-
Virpax Pharmaceuticals-($12M)--(0.0x)-
Lipella Pharmaceuticals$536K($5M)----
Allurion$15M($28M)1.6x1.7x(0.9x)-

This data is available for Pro users. Sign up to see all Vaxxinity competitors and their valuation data.

Start Free Trial

Vaxxinity VC Funding History

Before going public, Vaxxinity raised $33M in total equity funding, across 2 rounds.


Vaxxinity Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Aug-20Undisclosed stageMinistry of Health and Welfare (Taiwan)$18M--
Apr-20Series A-$15M--

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Vaxxinity

When was Vaxxinity founded?Vaxxinity was founded in 2021.
Where is Vaxxinity headquartered?Vaxxinity is headquartered in United States.
How many employees does Vaxxinity have?As of today, Vaxxinity has over 65 employees.
Is Vaxxinity publicly listed?Yes, Vaxxinity is a public company listed on OTCM.
What is the stock symbol of Vaxxinity?Vaxxinity trades under VAXX ticker.
When did Vaxxinity go public?Vaxxinity went public in 2021.
Who are competitors of Vaxxinity?Vaxxinity main competitors include Scorpius Holdings, Neovacs, Novaccess Global, M2Bio Sciences, Acutus Medical, Virpax Pharmaceuticals, Lipella Pharmaceuticals, Allurion, Lyra Therapeutics, Ocean Biomedical.
What is the current market cap of Vaxxinity?Vaxxinity's current market cap is $13K.
Is Vaxxinity profitable?No, Vaxxinity is not profitable.
How many companies Vaxxinity has acquired to date?Vaxxinity hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Vaxxinity has invested to date?Vaxxinity hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Vaxxinity

Lists including Vaxxinity

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial